Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

26
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
26
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

63
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
63
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

277
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
277
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

246
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
246
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

65
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
65
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

37
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
37

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.

EClinicalMedicine·2026
Same author

Impact of hospital restructuring on emergency department quality: a natural experiment.

Internal and emergency medicine·2026
Same author

Transcriptomic Evidence of Immune-Tumor Uncoupling Defines a High-Risk State in Uterine Corpus Endometrial Carcinoma.

International journal of molecular sciences·2026
Same author

TAPINTO: A Novel Algorithm for Tumor-Associated Antigen Prediction Based on Information about Target Overexpression.

Computational and structural biotechnology journal·2026
Same author

Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.

International journal of molecular sciences·2026
Same author

Zebrafish Model Reveals Early Electrocardiographic and Molecular Signatures of Doxorubicin-Induced Cardiotoxicity.

Cardiovascular toxicology·2026

Related Experiment Video

Updated: Oct 22, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

813

Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis.

Chi-Hone Lien1, Ming-Dar Lee1, Shun-Long Weng1,2

  • 1Hsinchu MacKay Memorial Hospital, Hsinchu 30071, Taiwan.

Life (Basel, Switzerland)
|August 27, 2021
PubMed
Summary

Colchicine treatment may reduce mortality risk in COVID-19 patients. However, this finding requires further confirmation from randomized controlled trials, as initial subgroup analysis showed no significant benefit.

Keywords:
COVID-19SARS-CoV-2colchicineimmunomodulationnovel coronavirus

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.2K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.3K

Related Experiment Videos

Last Updated: Oct 22, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

813
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.2K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.3K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Coronavirus disease 2019 (COVID-19) has caused significant global health burdens.
  • Colchicine, an anti-inflammatory drug, has been investigated for its potential therapeutic effects in COVID-19 patients.
  • Repurposing existing drugs like colchicine offers a potential strategy for managing the pandemic.

Purpose of the Study:

  • To systematically review and meta-analyze the available evidence on the efficacy and safety of colchicine treatment in patients with COVID-19.
  • To evaluate the impact of colchicine on mortality, mechanical ventilation rates, and side effects.
  • To assess potential discrepancies between overall findings and subgroup analyses, particularly those involving randomized controlled trials.

Main Methods:

  • A systematic literature search was conducted across multiple databases (PubMed, EMbase, medRxiv, Research Square) up to May 31, 2021.
  • Eleven studies involving 17,205 COVID-19 patients were included in the meta-analysis.
  • Statistical analyses, including odds ratios (OR) and confidence intervals (CI), were performed to assess treatment effects and heterogeneity (I²).

Main Results:

  • Colchicine treatment was associated with a significantly lower risk of mortality (OR: 0.57, 95% CI: 0.38-0.87).
  • A non-significant trend towards a lower rate of mechanical ventilation was observed (OR: 0.67, 95% CI: 0.39-1.15).
  • Reported side effects were mild and not significantly different between groups (OR: 2.03, 95% CI: 0.51-8.09).
  • Subgroup analysis of randomized controlled trials (RCTs) did not show a statistically significant difference in mortality (OR: 0.80, 95% CI: 0.44-1.46).

Conclusions:

  • The meta-analysis suggests that colchicine treatment may reduce mortality in COVID-19 patients.
  • However, the lack of significant benefit in the RCT subgroup analysis highlights the need for cautious interpretation.
  • Further high-quality randomized controlled studies are essential to definitively establish the role of colchicine in COVID-19 management.